Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free KLRS Stock Alerts

Kalaris Therapeutics (KLRS) Financials

Kalaris Therapeutics logo
$4.44 -0.05 (-1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$4.40 -0.04 (-0.79%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Kalaris Therapeutics

Annual Income Statements for Kalaris Therapeutics

This table shows Kalaris Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -24 -70 -172 -169 -190 -69 -43
Consolidated Net Income / (Loss)		 -24 -70 -172 -169 -190 -69 -43
Net Income / (Loss) Continuing Operations		 -24 -70 -172 -169 -190 -69 -43
Total Pre-Tax Income 		-24 -70 -171 -169 -191 -69 -43
Total Operating Income		 -27 -71 -170 -171 -200 -52 -46
Total Gross Profit		 0.17 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.17 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 27 71 170 171 200 52 46
Selling, General & Admin Expense		 11 22 49 52 48 6.69 15
Research & Development Expense		 16 50 121 119 133 45 31
Total Other Income / (Expense), net		 2.86 1.53 -1.14 2.23 9.36 -17 2.75
Other Income / (Expense), net		 0.80 0.20 -2.45 0.35 3.62 -15 2.75
Basic Earnings per Share		 ($18.54) ($2.59) ($2.74) ($2.20) ($42.09) ($51.77) ($2.85)
Weighted Average Basic Shares Outstanding		 1.29M 26.90M 62.78M 76.65M 4.52M 1.34M 15.27M
Diluted Earnings per Share		 ($18.54) ($2.59) ($2.74) ($2.20) ($42.09) ($51.77) ($2.85)
Weighted Average Diluted Shares Outstanding		 1.29M 26.90M 62.78M 76.65M 4.52M 1.34M 15.27M
Weighted Average Basic & Diluted Shares Outstanding		 1.29M 26.90M 62.78M 93.46M 114.87M 5.04M 22.93M

Quarterly Income Statements for Kalaris Therapeutics

This table shows Kalaris Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -44 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11
Consolidated Net Income / (Loss)		 -44 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11
Net Income / (Loss) Continuing Operations		 -44 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11
Total Pre-Tax Income 		-44 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11
Total Operating Income		 -47 -62 -2.56 -4.19 -38 -7.13 -10 -12 -13 -11 -12
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 47 62 2.56 4.19 38 7.13 10 12 13 11 12
Selling, General & Admin Expense		 13 10 0.60 0.98 1.83 3.28 4.32 3.82 3.62 3.64 4.26
Research & Development Expense		 34 33 1.96 3.21 36 3.85 6.03 8.44 9.13 7.16 7.57
Total Other Income / (Expense), net		 2.69 2.58 -0.84 -1.46 -0.24 -15 0.19 0.91 0.85 0.80 0.98
Interest Expense		 - - 0.08 0.50 0.82 1.31 - - - - 0.00
Other Income / (Expense), net		 1.17 1.21 -0.77 -0.96 0.58 -14 0.19 0.91 0.85 0.80 0.98
Basic Earnings per Share		 ($0.39) ($13.19) ($2.60) ($4.26) ($28.16) ($16.49) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46)
Weighted Average Basic Shares Outstanding		 113.89M 4.52M 1.31M 1.33M 1.35M 1.34M 4.05M 18.70M 18.70M 15.27M 23.72M
Diluted Earnings per Share		 ($0.39) ($13.19) ($2.60) ($4.26) ($28.16) ($16.49) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46)
Weighted Average Diluted Shares Outstanding		 113.89M 4.52M 1.31M 1.33M 1.35M 1.34M 4.05M 18.70M 18.70M 15.27M 23.72M
Weighted Average Basic & Diluted Shares Outstanding		 114.06M 114.87M 115.00M 115.37M 115.54M 5.04M 18.70M 18.70M 18.70M 22.93M 23.79M

Annual Cash Flow Statements for Kalaris Therapeutics

This table details how cash moves in and out of Kalaris Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 36 62 80 -96 -16 -1.53 97
Net Cash From Operating Activities		 -20 -61 -106 -142 -124 -21 -38
Net Cash From Continuing Operating Activities		 -20 -61 -106 -142 -124 -21 -38
Net Income / (Loss) Continuing Operations		 -24 -70 -172 -169 -190 -69 -43
Consolidated Net Income / (Loss)		 -24 -70 -172 -169 -190 -69 -43
Depreciation Expense		 0.02 0.07 0.19 0.72 0.40 0.00 0.01
Amortization Expense		 -0.62 0.50 1.20 -1.08 -3.70 0.00 -0.40
Non-Cash Adjustments To Reconcile Net Income		 2.89 9.73 45 43 67 53 3.25
Changes in Operating Assets and Liabilities, net		 1.39 -1.33 19 -16 2.03 -4.21 2.20
Net Cash From Investing Activities		 -65 -169 186 -80 38 0.00 -20
Net Cash From Continuing Investing Activities		 -65 -169 186 -80 38 0.00 -20
Purchase of Property, Plant & Equipment		 -0.34 -0.24 -0.03 0.00 - 0.00 -0.20
Purchase of Investments		 -119 -300 -77 -229 -126 0.00 -35
Sale and/or Maturity of Investments		 55 131 263 148 164 0.00 15
Net Cash From Financing Activities		 121 292 0.23 127 70 19 155
Net Cash From Continuing Financing Activities		 121 292 0.23 127 70 19 155
Repurchase of Common Equity		 0.00 -3.47 - - - 0.00 -1.67
Issuance of Debt		 - - - - - 20 7.50
Issuance of Preferred Equity		 121 0.00 - - - 1.59 0.00
Issuance of Common Equity		 0.00 295 0.00 127 70 0.00 50
Other Financing Activities, net		 - 0.00 0.23 0.00 - -2.42 99

Quarterly Cash Flow Statements for Kalaris Therapeutics

This table details how cash moves in and out of Kalaris Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -101 -5.51 2.06 1.01 -4.33 -0.27 100 -13 -46 56 -64
Net Cash From Operating Activities		 -34 -31 -4.52 -3.97 -4.33 -7.85 -7.44 -13 -11 -7.06 -12
Net Cash From Continuing Operating Activities		 -34 -31 -4.52 -3.97 -4.33 -7.85 -7.44 -13 -11 -7.06 -12
Net Income / (Loss) Continuing Operations		 -44 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11
Consolidated Net Income / (Loss)		 -44 -60 -3.41 -5.65 -38 -22 -10 -11 -12 -10.00 -11
Depreciation Expense		 0.09 0.14 - - - - 0.00 - - 0.01 0.01
Amortization Expense		 -1.23 -1.21 - - - - 0.00 - - -0.32 -0.22
Non-Cash Adjustments To Reconcile Net Income		 14 33 0.72 2.40 33 16 2.00 -0.64 0.65 0.01 0.62
Changes in Operating Assets and Liabilities, net		 -3.08 -2.64 -1.83 -0.73 0.64 -2.29 0.75 -0.55 -0.01 3.24 -1.14
Net Cash From Investing Activities		 -67 25 0.00 - - - 0.00 - -35 15 -50
Net Cash From Continuing Investing Activities		 -67 25 0.00 - - - 0.00 - -35 15 -50
Purchase of Investments		 -102 -9.78 - - - - 0.00 - - - -70
Sale and/or Maturity of Investments		 35 35 - - - - 0.00 - - - 20
Net Cash From Financing Activities		 - 0.01 6.58 4.98 0.00 7.58 107 - - 48 -1.70
Net Cash From Continuing Financing Activities		 - 0.01 6.58 4.98 0.00 7.58 107 - - 48 -1.70
Issuance of Debt		 - - 4.99 5.00 - 9.97 7.50 - - - 0.00
Other Financing Activities, net		 - - -0.01 -0.02 0.00 -2.40 100 - - -0.59 -1.70

Annual Balance Sheets for Kalaris Therapeutics

This table presents Kalaris Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 139 371 287 277 191 6.16 122
Total Current Assets		 127 361 253 243 188 2.61 119
Cash & Equivalents		 61 123 202 106 90 1.64 98
Short-Term Investments		 65 234 46 128 94 0.00 20
Prepaid Expenses		 0.68 4.54 5.18 9.10 3.49 0.97 0.83
Other Current Assets		 0.30 0.00 - - - - 0.00
Plant, Property, & Equipment, net		 0.35 0.81 1.55 0.93 0.00 0.00 0.00
Total Noncurrent Assets		 12 8.69 32 33 3.16 3.56 2.93
Long-Term Investments		 - - - - - - 0.00
Other Noncurrent Operating Assets		 12 8.69 32 33 3.16 3.56 2.93
Total Liabilities & Shareholders' Equity		 139 371 287 277 191 6.16 122
Total Liabilities		 18 18 61 53 45 57 43
Total Current Liabilities		 9.11 12 38 24 28 25 9.71
Accounts Payable		 0.88 1.54 10 3.00 6.76 1.56 1.28
Accrued Expenses		 5.16 7.53 20 14 10 2.20 8.12
Other Current Liabilities		 3.07 3.23 6.59 7.22 12 1.41 0.32
Total Noncurrent Liabilities		 8.69 5.46 23 28 17 32 33
Other Noncurrent Operating Liabilities		 8.69 5.46 23 - - 32 33
Total Equity & Noncontrolling Interests		 -52 353 225 225 146 -97 79
Total Preferred & Common Equity		 -52 353 225 225 146 -97 79
Total Common Equity		 -52 353 225 225 146 -97 79
Common Stock		 3.75 478 522 691 802 20 239
Retained Earnings		 -55 -125 -297 -466 -656 -117 -160
Accumulated Other Comprehensive Income / (Loss)		 0.07 -0.11 -0.16 -0.47 -0.06 0.00 0.01

Quarterly Balance Sheets for Kalaris Therapeutics

This table presents Kalaris Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 248 144 131 123 103 93 81 110
Total Current Assets		 220 141 130 123 102 92 78 98
Cash & Equivalents		 96 86 105 117 101 88 42 34
Short-Term Investments		 118 54 25 5.00 - - 35 63
Prepaid Expenses		 6.47 0.77 0.23 0.63 1.22 3.23 1.18 0.86
Other Current Assets		 - - - - - - - 0.39
Plant, Property, & Equipment, net		 0.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 28 2.66 1.05 0.00 0.91 1.19 2.99 11
Long-Term Investments		 - - - - - - - 7.65
Other Noncurrent Operating Assets		 28 2.66 1.05 0.00 0.91 1.19 2.99 3.69
Total Liabilities & Shareholders' Equity		 248 144 131 123 103 93 81 110
Total Liabilities		 53 24 11 1.41 39 40 39 41
Total Current Liabilities		 33 7.66 2.36 1.41 7.14 7.65 6.07 8.08
Accounts Payable		 3.93 0.77 0.11 0.05 2.37 3.68 0.49 0.91
Accrued Expenses		 16 4.60 1.58 1.36 4.40 3.97 5.20 6.86
Other Current Liabilities		 13 2.30 0.67 0.00 0.00 0.00 0.38 0.32
Total Noncurrent Liabilities		 20 16 8.34 0.00 32 32 33 33
Other Noncurrent Operating Liabilities		 20 16 8.34 0.00 32 32 33 33
Total Equity & Noncontrolling Interests		 195 120 120 121 64 53 42 69
Total Preferred & Common Equity		 195 120 120 121 64 53 42 69
Total Common Equity		 195 120 120 121 64 53 42 69
Common Stock		 792 807 813 818 191 191 192 239
Retained Earnings		 -596 -686 -693 -697 -127 -138 -150 -171
Accumulated Other Comprehensive Income / (Loss)		 -0.20 -0.14 -0.14 -0.13 - - 0.01 -0.05

Annual Metrics And Ratios for Kalaris Therapeutics

This table displays calculated financial ratios and metrics derived from Kalaris Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 65,106,873.00 65,140,831.00 93,162,961.00 114,063,336.00 115,536,550.00 18,702,418.00
DEI Adjusted Shares Outstanding		 0.00 2,830,734.00 2,832,210.00 4,050,564.00 4,959,275.00 5,023,328.00 18,702,418.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -24.65 -60.72 -41.65 -38.40 -13.77 -2.32
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -166.13% -142.25% -0.19% -16.57% 66.70% 34.12%
EBIT Growth		 0.00% -174.53% -142.24% 0.82% -14.88% 66.14% 34.70%
NOPAT Growth		 0.00% -167.06% -138.14% -0.82% -16.76% 74.12% 10.79%
Net Income Growth		 0.00% -192.73% -146.42% 1.89% -12.87% 63.68% 37.20%
EPS Growth		 0.00% 86.03% -5.79% 19.71% -12.87% 63.68% 94.49%
Operating Cash Flow Growth		 0.00% -201.72% -74.84% -33.61% 12.39% 83.39% -85.63%
Free Cash Flow Firm Growth		 0.00% 0.00% -94.25% -62.82% 38.46% 74.86% -3.37%
Invested Capital Growth		 0.00% 26.79% -601.04% 182.90% -213.55% -52.06% -19.72%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -22.59% 8.85% -12.41% 38.46% 17.75%
EBIT Q/Q Growth		 0.00% 0.00% -22.14% 9.32% -12.46% 37.85% 16.39%
NOPAT Q/Q Growth		 0.00% 0.00% -21.79% 8.23% -12.35% 51.65% 17.87%
Net Income Q/Q Growth		 0.00% 0.00% -23.52% 10.51% -12.77% 35.26% 3.62%
EPS Q/Q Growth		 0.00% 0.00% -156.96% 21.43% -12.77% 35.26% -18.26%
Operating Cash Flow Q/Q Growth		 0.00% -25.16% -7.02% -2.53% 0.67% 52.54% 55.49%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -26.04% 15.31% 72.86% -423.97%
Invested Capital Q/Q Growth		 0.00% 0.00% -167.71% 274.12% -19.63% -4,363.17% -11.48%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -16,063.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -16,182.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -15,699.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -14,447.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.59% 99.84% 99.93% 100.00% 100.08%
Interest Burden Percent		 92.03% 98.13% 99.24% 98.90% 97.08% 104.06% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.60% -29.40% -59.47% -75.02% -102.85% -145.36% -308.10%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -853.17% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -18.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -17.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 8.30% -18.68% -59.47% -75.02% -102.85% -75.10% 194.52%
Return on Equity Simple (ROE_SIMPLE)		 46.29% -19.77% -76.34% -75.14% -130.62% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -50 -119 -120 -140 -36 -32
NOPAT Margin		 -11,327.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.08% -8.24% -17.57% -21.54% -27.08% -44.12% -22.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -86.15% 46.98% -40.99%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,435.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 9,847.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 16,282.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -71 -172 -171 -196 -66 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -71 -171 -171 -200 -66 -44
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 7.09 3.74 2.13 0.53 0.00 2.00
Price to Tangible Book Value (P/TBV)		 0.00 7.09 3.74 2.13 0.53 0.00 2.00
Price to Revenue (P/Rev)		 1,674.24 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 14.38 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,959.39 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.13 0.11 -0.39 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.13 0.11 0.00 0.00
Financial Leverage		 -1.04 -1.02 -1.05 -1.01 -1.01 -1.57 -3.55
Leverage Ratio		 1.15 1.07 1.14 1.25 1.26 2.07 4.54
Compound Leverage Factor		 1.06 1.05 1.13 1.24 1.23 2.15 4.54
Debt to Total Capital		 0.00% 0.00% 0.00% 11.17% 10.25% -62.88% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -62.88% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 11.17% 10.25% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 142.35% 0.00% 0.00% 0.00% 0.00% -148.02% 0.00%
Common Equity to Total Capital		 -42.35% 100.00% 100.00% 88.83% 89.75% 310.90% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.16 -0.08 -0.29 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 1.20 0.84 -0.27 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.16 -0.08 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.24 -0.12 -0.54 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 1.72 1.20 -0.49 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.24 -0.12 0.00 0.00
Altman Z-Score		 9.16 84.59 5.71 2.01 -6.17 -65.87 0.27
Noncontrolling Interest Sharing Ratio		 142.35% 36.47% 0.00% 0.00% 0.00% 48.34% 163.13%
Liquidity Ratios		 - - - - - - -
Current Ratio		 13.98 29.39 6.69 9.99 6.61 0.11 12.23
Quick Ratio		 13.87 29.02 6.56 9.61 6.49 0.07 12.15
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -51 -99 -162 -99 -25 -26
Operating Cash Flow to CapEx		 -5,945.43% -25,877.02% -408,919.23% 0.00% 0.00% 0.00% -19,185.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -9.26 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -7.65 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -7.65 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.47 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -4.45 -3.26 -23 19 -22 -33 -39
Invested Capital Turnover		 -0.04 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.19 -20 42 -40 -11 -6.45
Enterprise Value (EV)		 323 2,146 595 272 -90 112 40
Market Capitalization		 276 2,503 843 478 78 49 158
Book Value per Share		 ($40.05) $5.42 $3.46 $2.41 $1.28 ($0.84) $4.21
Tangible Book Value per Share		 ($40.05) $5.42 $3.46 $2.41 $1.28 ($0.84) $4.21
Total Capital		 122 353 225 253 162 -31 79
Total Debt		 0.00 0.00 0.00 28 17 20 0.00
Total Long-Term Debt		 0.00 0.00 0.00 28 17 0.00 0.00
Net Debt		 -126 -356 -248 -206 -167 18 -118
Capital Expenditures (CapEx)		 0.34 0.24 0.03 0.00 0.00 0.00 0.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.87 -7.30 -33 -15 -25 -4.20 -8.89
Debt-free Net Working Capital (DFNWC)		 118 349 215 219 159 -2.56 109
Net Working Capital (NWC)		 118 349 215 219 159 -22 109
Net Nonoperating Expense (NNE)		 5.15 20 53 49 50 33 11
Net Nonoperating Obligations (NNO)		 -126 -356 -248 -206 -167 18 -118
Total Depreciation and Amortization (D&A)		 -0.60 0.58 1.39 -0.35 -3.30 0.00 -0.39
Debt-free, Cash-free Net Working Capital to Revenue		 -4,769.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 71,640.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 71,640.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.59) ($2.74) ($2.20) ($42.09) ($11.73) ($2.85)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 65.11M 65.35M 76.65M 4.52M 5.01M 15.27M
Adjusted Diluted Earnings per Share		 $0.00 ($2.59) ($2.74) ($2.20) ($42.09) ($11.73) ($2.85)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 65.11M 65.35M 76.65M 4.52M 5.01M 15.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.59) ($2.74) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 26.90M 62.78M 93.46M 4.99M 5.04M 22.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -50 -119 -120 -127 -36 -32
Normalized NOPAT Margin		 -11,327.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -14,447.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -24.61 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -13.41 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -24.61 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -13.41 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -4.98% 0.00% 0.00% 0.00% 0.00% -3.84%

Quarterly Metrics And Ratios for Kalaris Therapeutics

This table displays calculated financial ratios and metrics derived from Kalaris Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 113,868,112.00 114,063,336.00 114,869,175.00 115,003,325.00 115,365,282.00 115,536,550.00 5,043,357.00 18,702,418.00 18,702,418.00 18,702,418.00 22,928,303.00
DEI Adjusted Shares Outstanding		 4,950,787.00 4,959,275.00 4,994,312.00 5,000,145.00 5,015,882.00 5,023,328.00 5,043,357.00 18,702,418.00 18,702,418.00 18,702,418.00 22,928,303.00
DEI Earnings Per Adjusted Shares Outstanding		 -8.94 -12.04 -0.68 -1.13 -7.59 -4.38 -2.02 -0.61 -0.64 -0.53 -0.47
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -9.39% -54.76% 92.29% 89.09% 20.60% 66.73% -205.23% -120.35% 68.09% 50.26% -8.91%
EBIT Growth		 -7.15% -55.12% 92.17% 88.99% 18.62% 66.14% -205.23% -120.35% 68.09% 51.74% -6.84%
NOPAT Growth		 -9.34% -54.33% 94.07% 91.15% 19.40% 88.57% -303.98% -192.72% 66.34% -51.42% -14.28%
Net Income Growth		 -5.23% -56.53% 91.73% 87.52% 13.98% 63.10% -199.27% -100.89% 68.77% 54.61% -6.47%
EPS Growth		 22.00% -56.53% 91.73% 87.52% 13.98% 63.10% 3.08% 85.68% 97.73% 96.06% 81.75%
Operating Cash Flow Growth		 1.85% 2.65% 85.92% 85.36% 87.45% 74.46% -64.59% -215.76% -161.91% 10.11% -55.64%
Free Cash Flow Firm Growth		 7.04% 95.40% 129.94% 63.50% -69.75% 292.58% 5.35% 257.80% 158.25% -117.84% -192.91%
Invested Capital Growth		 -65.28% -213.55% -122.28% 46.51% 95.92% -52.06% -84.62% -278.87% -4,693.18% -19.72% 2.10%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.60% -32.64% 94.65% -54.73% -623.53% 44.41% 50.95% -11.70% -4.79% 13.37% -7.40%
EBIT Q/Q Growth		 2.11% -33.63% 94.56% -54.73% -623.53% 44.41% 50.95% -11.70% -4.79% 15.94% -8.58%
NOPAT Q/Q Growth		 0.73% -32.89% 95.89% -63.36% -803.96% 81.15% -45.16% -18.37% -3.96% 15.23% -9.55%
Net Income Q/Q Growth		 2.20% -34.84% 94.29% -65.84% -574.05% 42.16% 53.71% -11.32% -4.79% 15.94% -8.58%
EPS Q/Q Growth		 18.75% -34.84% 94.29% -65.84% -574.05% 42.16% 84.72% 75.79% -4.92% -1.56% 29.23%
Operating Cash Flow Q/Q Growth		 -27.11% 10.85% 85.29% 12.17% -8.97% -81.44% 5.22% -68.51% 9.62% 37.73% -64.11%
Free Cash Flow Firm Q/Q Growth		 14.74% 87.49% 387.20% -219.18% -296.46% 114.19% 57.11% 78.52% 46.35% -104.35% -718.10%
Invested Capital Q/Q Growth		 -3.22% -19.63% 6.62% 53.61% 92.14% -4,363.17% -13.38% 4.80% 0.50% -11.48% 7.29%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.79% 100.00% 100.00% 100.00% 100.00% 100.34% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.68% 97.76% 102.34% 109.69% 102.19% 106.32% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -75.29% -102.85% -97.23% -64.70% -67.52% -145.36% -82.42% -82.19% -55.30% -308.10% -66.60%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -75.29% -102.85% -97.23% -64.70% -67.52% -75.10% -82.42% -82.19% -55.30% 194.52% -66.60%
Return on Equity Simple (ROE_SIMPLE)		 -86.45% 0.00% -126.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -44 -1.79 -2.93 -26 -4.99 -7.25 -8.58 -8.92 -7.56 -8.28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.78% -8.59% -0.94% -1.45% -6.92% -22.80% -2.44% -2.54% -2.99% -4.87% -2.50%
Return On Investment Capital (ROIC_SIMPLE)		 - -26.89% -1.49% -2.44% -21.87% 6.48% -11.35% -16.15% -21.30% -9.59% -12.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -46 -61 -3.33 -5.15 -37 -21 -10 -11 -12 -10.00 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -62 -3.33 -5.15 -37 -21 -10 -11 -12 -10 -11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.25 0.53 0.72 0.69 0.77 0.00 0.63 0.94 2.58 2.00 1.93
Price to Tangible Book Value (P/TBV)		 1.25 0.53 0.72 0.69 0.77 0.00 0.63 0.94 2.58 2.00 1.93
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.11 0.00 0.00 0.00 -0.39 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.06 -1.01 -1.09 -1.08 -1.06 -1.57 -1.31 -1.26 -1.22 -3.55 -1.55
Leverage Ratio		 1.21 1.26 1.24 1.18 1.17 2.07 1.34 1.29 1.25 4.54 1.61
Compound Leverage Factor		 1.17 1.24 1.27 1.30 1.20 2.20 1.34 1.29 1.25 4.54 1.61
Debt to Total Capital		 0.00% 10.25% 0.00% 0.00% 0.00% -62.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -62.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 10.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -148.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 89.75% 100.00% 100.00% 100.00% 310.90% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.08 0.00 0.00 0.00 -0.29 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.84 0.00 0.00 0.00 -0.27 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.12 0.00 0.00 0.00 -0.54 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 1.20 0.00 0.00 0.00 -0.49 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.30 -3.84 -3.43 -1.70 31.86 -41.37 -0.32 -0.65 -0.35 1.17 0.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 48.34% 0.00% 0.00% 0.00% 163.13% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.65 6.61 18.48 55.08 86.78 0.11 14.31 11.98 12.89 12.23 12.19
Quick Ratio		 6.46 6.49 18.38 54.98 86.33 0.07 14.14 11.56 12.70 12.15 12.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -26 -3.22 9.26 -11 -44 6.21 9.75 17 25 -1.11 -9.06
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,511.76% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 118.69 -22.11 -53.68 4.74 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -57.96 -7.96 -5.31 -6.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -57.96 -7.96 -5.31 -6.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -18 -22 -20 -9.32 -0.73 -33 -37 -35 -35 -39 -36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.10 -40 -11 8.10 17 -11 -17 -26 -34 -6.45 0.78
Enterprise Value (EV)		 31 -90 -54 -46 -29 112 -60 -38 31 40 27
Market Capitalization		 245 78 87 83 93 49 40 50 108 158 132
Book Value per Share		 $1.72 $1.28 $1.05 $1.05 $1.05 ($0.84) $12.67 $2.84 $2.24 $4.21 $2.89
Tangible Book Value per Share		 $1.72 $1.28 $1.05 $1.05 $1.05 ($0.84) $12.67 $2.84 $2.24 $4.21 $2.89
Total Capital		 195 162 120 120 121 -31 64 53 42 79 69
Total Debt		 0.00 17 0.00 0.00 0.00 20 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -213 -167 -141 -130 -122 18 -101 -88 -77 -118 -105
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -25 -6.70 -2.03 -0.73 -4.20 -5.93 -4.43 -4.88 -8.89 -6.83
Debt-free Net Working Capital (DFNWC)		 187 159 134 128 121 -2.56 95 84 72 109 90
Net Working Capital (NWC)		 187 159 134 128 121 -22 95 84 72 109 90
Net Nonoperating Expense (NNE)		 11 16 1.61 2.72 12 17 2.95 2.77 2.98 2.44 2.57
Net Nonoperating Obligations (NNO)		 -213 -167 -141 -130 -122 18 -101 -88 -77 -118 -105
Total Depreciation and Amortization (D&A)		 -1.15 -1.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 -0.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.39) ($303.37) ($5.98) ($1.15) ($0.92) ($379.27) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 113.89M 196.71K 4.99M 5.01M 5.02M 58.08K 4.05M 18.70M 18.70M 15.27M 23.72M
Adjusted Diluted Earnings per Share		 ($0.39) ($303.37) ($5.98) ($1.15) ($0.92) ($379.27) ($2.52) ($0.61) ($0.64) ($0.65) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 113.89M 196.71K 4.99M 5.01M 5.02M 58.08K 4.05M 18.70M 18.70M 15.27M 23.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($303.37) $0.00 $0.00 $0.00 ($379.27) $0.00 $0.00 $0.00 ($0.65) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 114.06M 4.99M 5.00M 5.02M 5.02M 219.28K 18.70M 18.70M 18.70M 22.93M 23.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -44 -1.79 -2.93 -26 -4.99 -7.25 -8.58 -8.92 -7.56 -8.28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -42.68 -10.32 -45.73 -15.83 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -23.00 -5.87 -32.51 -3.81 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -42.68 -10.32 -45.73 -15.83 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -23.00 -5.87 -32.51 -3.81 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.84% 0.00%

Financials Breakdown Chart

Kalaris Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kalaris Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Kalaris Therapeutics' net income appears to be on an upward trend, with a most recent value of -$43.44 million in 2025, rising from -$23.84 million in 2019. The previous period was -$69.17 million in 2024. See where experts think Kalaris Therapeutics is headed by visiting Kalaris Therapeutics' forecast page.

Kalaris Therapeutics' total operating income in 2025 was -$46.15 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $46.15 million

Over the last 6 years, Kalaris Therapeutics' total revenue changed from $165 thousand in 2019 to $0.00 in 2025, a change of -100.0%.

Kalaris Therapeutics' total liabilities were at $42.92 million at the end of 2025, a 24.4% decrease from 2024, and a 141.2% increase since 2019.

In the past 6 years, Kalaris Therapeutics' cash and equivalents has ranged from $1.64 million in 2024 to $201.66 million in 2021, and is currently $98.05 million as of their latest financial filing in 2025.

Over the last 6 years, Kalaris Therapeutics' book value per share changed from -40.05 in 2019 to 4.21 in 2025, a change of -110.5%.


Related Companies

Financial statements for NASDAQ:KLRS last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A better retirement stock than Berkshire?
Whitney Tilson - the analyst CNBC called 'The Prophet' for early calls on Netflix, Apple, and Amazon - says he...
Stansberry Research | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel